Detail akcie Pulmonx Rg online

Business Summary: Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Pulmonx Corp revenues increased 28% to $68.7M. Net loss increased 3% to $60.8M. Revenues reflect United States segment increase of 41% to $45.9M, Europe, Middle-East and Africa ("EMEA") segment increase of 7% to $19.3M. Higher net loss reflects Selling, general and administrative increase of 10% to $76.6M (expense), Stock-based Compensation in SGA increase of 32% to $18M (expense).